RAC Charts, page-927

I’ve gone deep on my research. Over 40 years for this investment. Plus in-depth look at chemo.

The name Bisantrene has been used throughout development so there is no attempt to obfuscate. All the background trials are easy to find.

As for other biotechs, obfuscation is unfortunately common - both in naming (renaming) of drugs and vague reporting of results.

Biotech code of practice is weak and also ASX seem to be weak in their enforcement of it.

At least Dr Tillett has said he wants to lift reporting standards.